Nexentis Technologies Inc.
$1.67 -$0.13 (-7.22%) 1D Pre-marketKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
From its Jun 22 high, the share price fell 87%.
Peak close $13.00 on Jun 22; trough close $1.67 on Jul 27. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -87% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 23
The stock moved -55.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 23 -
Jun 22
The stock moved +155.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 22
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Nexentis Technologies Inc.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting spe…
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.